Published in Clin Cancer Res on February 15, 2006
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res (2008) 3.51
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene (2008) 2.31
Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis (2011) 1.70
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res (2009) 1.44
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res (2008) 1.42
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer (2009) 1.41
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One (2012) 1.33
DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol (2011) 1.29
In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer. Horm Cancer (2010) 1.29
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res (2009) 1.27
EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol (2011) 1.21
Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer (2010) 1.18
Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res (2011) 1.16
Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate (2010) 1.14
H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependency. EMBO J (2011) 1.12
EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev (2012) 1.07
Overexpression of MACC1 and Its significance in human Breast Cancer Progression. Cell Biosci (2013) 1.04
Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res (2015) 1.04
microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp Ther Med (2011) 1.03
Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol (2014) 1.00
Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers (Basel) (2011) 1.00
Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics (2013) 0.99
EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res (2013) 0.96
CR Cistrome: a ChIP-Seq database for chromatin regulators and histone modification linkages in human and mouse. Nucleic Acids Res (2013) 0.95
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol (2012) 0.95
Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer (2009) 0.94
EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One (2012) 0.94
A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level. J Biol Chem (2012) 0.94
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer (2016) 0.93
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle (2013) 0.93
Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat (2011) 0.93
EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat (2013) 0.92
Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One (2014) 0.92
Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med (2010) 0.90
Context-dependent actions of Polycomb repressors in cancer. Oncogene (2015) 0.89
The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol (2006) 0.88
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis. Oncotarget (2016) 0.88
Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells. PLoS One (2012) 0.85
Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression. Breast Cancer Res Treat (2012) 0.84
Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. Oncotarget (2016) 0.82
Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor. Mol Cancer (2010) 0.82
Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis. Biol Res Nurs (2013) 0.81
NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget (2015) 0.81
EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features. Diagn Pathol (2016) 0.81
Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? Mol Oncol (2016) 0.81
YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol (2014) 0.80
Current Status of Long Non-Coding RNAs in Human Breast Cancer. Int J Mol Sci (2016) 0.79
Role of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population. Int J Mol Sci (2014) 0.79
The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiat Oncol (2014) 0.79
Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis. PLoS One (2015) 0.79
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis. Neoplasia (2014) 0.78
Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep (2016) 0.78
H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol Med (2011) 0.78
Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. Sci Rep (2016) 0.78
SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic Acids Res (2014) 0.78
Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells. Curr Pharmacol Rep (2015) 0.77
Polycomb Repressive Complex 2 regulates lineage fidelity during embryonic stem cell differentiation. PLoS One (2014) 0.77
Downregulation of Enhancer of Zeste Homolog 2 (EZH2) is essential for the Induction of Autophagy and Apoptosis in Colorectal Cancer Cells. Genes (Basel) (2016) 0.76
Role of epigenetic modifications in luminal breast cancer. Epigenomics (2015) 0.76
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. Clin Epigenetics (2015) 0.76
Role of HOTAIR in the diagnosis and prognosis of acute leukemia. Oncol Rep (2016) 0.76
Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma. Virchows Arch (2014) 0.76
Proximal and distal regulation of the HYAL1 gene cluster by the estrogen receptor α in breast cancer cells. Oncotarget (2016) 0.75
High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy. Biomed Res Int (2013) 0.75
Significance of EZH2 expression in canine mammary tumors. BMC Vet Res (2016) 0.75
KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling. Int J Clin Exp Pathol (2013) 0.75
Enzymatic assays for assessing histone deubiquitylation activity. Methods (2011) 0.75
Ezh2, a novel target in detection and therapy of breast cancer. Onco Targets Ther (2017) 0.75
MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep (2017) 0.75
Bivalent Epigenetic Control of Oncofetal Gene Expression in Cancer. Mol Cell Biol (2017) 0.75
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. Diseases (2017) 0.75
MiR-340 Inhibits Triple-Negative Breast Cancer Progression by Reversing EZH2 Mediated miRNAs Dysregulated Expressions. J Cancer (2017) 0.75
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
Effect of the World Health Organization checklist on patient outcomes: a stepped wedge cluster randomized controlled trial. Ann Surg (2015) 3.26
Malignant melanoma--diagnosis, treatment and follow-up in Norway. Tidsskr Nor Laegeforen (2013) 3.21
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res (2007) 2.57
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res (2005) 2.00
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res (2003) 1.96
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res (2003) 1.89
Nonresponse in a community cohort study: predictors and consequences for exposure-disease associations. J Clin Epidemiol (2002) 1.75
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev (2005) 1.74
Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res (2003) 1.74
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther (2006) 1.64
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res (2005) 1.51
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res (2005) 1.49
Occupational airborne exposure and the incidence of respiratory symptoms and asthma. Am J Respir Crit Care Med (2002) 1.46
Contribution of follow-up of nonresponders to prevalence and risk estimates: a Norwegian respiratory health survey. Am J Epidemiol (2003) 1.43
Comparison of telephone and postal survey modes on respiratory symptoms and risk factors. Am J Epidemiol (2002) 1.40
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol (2004) 1.39
Secondary breast cancer: a 5-year population-based study with review of the literature. APMIS (2009) 1.33
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol (2004) 1.31
Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One (2008) 1.27
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21
Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res (2013) 1.21
Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid (2006) 1.21
Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res (2006) 1.19
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res (2011) 1.19
Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer (2010) 1.18
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer (2013) 1.17
Tumor-vascular interactions and tumor dormancy. APMIS (2008) 1.16
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol (2008) 1.15
Patient safety in surgical environments: cross-countries comparison of psychometric properties and results of the Norwegian version of the Hospital Survey on Patient Safety. BMC Health Serv Res (2010) 1.14
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.12
Biologic markers in endometrial cancer treatment. APMIS (2009) 1.12
Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A (2009) 1.12
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res (2008) 1.11
Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res (2009) 1.11
NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene (2002) 1.09
Frequency of the basal-like phenotype in African breast cancer. APMIS (2007) 1.09
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol (2012) 1.06
Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer (2002) 1.06
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS (2009) 1.06
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer (2010) 1.05
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res (2002) 1.03
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One (2011) 1.03
Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer (2008) 1.03
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One (2013) 1.02
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. J Magn Reson Imaging (2013) 1.02
Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS (2008) 1.02
Health related quality of life after extremely preterm birth: a matched controlled cohort study. Health Qual Life Outcomes (2010) 1.01
A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer (2005) 1.01
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol (2008) 1.00
Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch (2005) 0.97
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res (2013) 0.97
Pseudoaneurysm of the abdominal aorta due to a needle-like osteophyte on the first lumbar vertebra. J Vasc Surg (2007) 0.96
The relationship between in-hospital information and patient satisfaction after acute myocardial infarction. Eur J Cardiovasc Nurs (2006) 0.95
Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age. Int J Colorectal Dis (2011) 0.95
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat (2013) 0.95
Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov (2013) 0.94
Efficient in vivo vascularization of tissue-engineering scaffolds. J Tissue Eng Regen Med (2010) 0.94
Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol (2012) 0.94
The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment. Scand J Urol Nephrol (2004) 0.93
Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer (2012) 0.92
Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol (2004) 0.92
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol (2006) 0.92
Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users. Breast Cancer Res (2012) 0.92
Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. Stem Cell Res Ther (2013) 0.91
MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol (2003) 0.91
Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Res Treat (2011) 0.91